Table 1.
Patient characteristics
| Arm 1 (n =14) | Arm 2 (n = 12) | Arm 3A (n =16) | Arm 3B (n =5) | Arm 4a (n =13) | |
|---|---|---|---|---|---|
| Age (years) | |||||
| Mean (SD) | 57 (12) | 63 (9) | 52 (13) | 49 (8) | 55 (14) |
| Range | 35-80 | 44-75 | 31-71 | 39-59 | 27-74 |
| Age group (years) | |||||
| > 18-65 | 12 | 8 | 13 | 5 | 10 |
| >65 | 2 | 4 | 3 | - | 3 |
| Race | |||||
| Caucasian | 11 | 12 | 15 | 5 | 10 |
| Black | 3 | - | 1 | - | 2 |
| Asian | - | - | - | - | 1 |
| Sex | |||||
| Male | 5 | 9 | 10 | 1 | 5 |
| Female | 9 | 3 | 6 | 4 | 8 |
| Baseline WHO performance status | |||||
| 0 | 3 | 2 | 2 | 2 | 3 |
| 1 | 9 | 10 | 13 | 3 | 9 |
| 2 | 2 | - | - | - | 1 |
| Unknown | - | - | 1 | - | - |
| Primary tumor type | |||||
| Lung | - | 1 | 7 | 1 | 8 |
| Colorectal | 9 | 1 | - | 3 | - |
| Pancreas | - | - | 3 | - | 1 |
| Breast | 1 | - | 2 | - | - |
| Renal cell | 1 | 1 | - | - | - |
| Prostate | - | 2 | - | - | - |
| Otherb | 3 | 7 | 4 | 1 | 4 |
| Relevant surgery | 14 | 12 | 14 | 5 | 12 |
| Previous immunotherapy/hormonal therapy | 1 | 3 | 1 | 0 | 0 |
| Previous radiotherapy | 6 | 7 | 11 | 2 | 9 |
| Previous chemotherapy | 13 | 11 | 16 | 5 | 13 |
| 1 regimen | 2 | 1 | 3 | 0 | 2 |
| 2 regimens | 2 | 3 | 1 | 2 | 1 |
| 3 regimens | 1 | 2 | 8 | 0 | 5 |
| >3 regimens | 8 | 5 | 4 | 3 | 5 |
a
Includes one patient who did not receive study treatment and was excluded from the safety analysis
b
Other tumor types included: abdomen, biliary tract, bladder, bone, esophagus, neurofibrosarcoma, occipital, ovary, peritoneum, pleura, prostate, rectal, renal/pelvis/ureter, skin/soft tissue, thyroid, unknown
Arm 1: cediranib+mFOLFOX6; arm 2: cediranib+docetaxel; arm 3A: cediranib+irinotecan; arm 3B: cediranib + irinotecan and cetuximab; arm 4: cediranib+pemetrexed